Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
DBDBV Technologies S.A. logo

DBV Technologies S.A. (DBVT)

NASDAQ Global Select · Currency in USD
$9.75 ▲ +0.07 (+0.72%)
At close: Oct 23, 4:00 PM ET. Market closed.
$10.00 ▲ +0.25 (+2.56%)
After hours: Oct 23, 4:30 PM ET

Summary

Previous Close
$9.68
Open
$9.64
Day's Range
$9.46 – $9.78
52 Week Range
$8.63 – $26.19
Volume
258,344
Avg. Volume
343,853
Market Cap
$233.24M
Beta (5Y Monthly)
-0.21
PE Ratio (TTM)
--
EPS (TTM)
-$2.03
Earnings Date
Oct 28, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$46.33

Profile: DBV Technologies S.A.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
161
CEO
Daniel Tassé

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy.

Earnings

Next report: Wed, Oct 28, 2026
EPS estimate -$0.16 · Revenue est. $664.00K
DateEst.Actual
Jul 16, 2026-$0.12-$0.14Miss
Apr 30, 2026-$0.14-$0.56Miss
Mar 27, 2026-$1.30-$1.15Beat
Oct 28, 2025-$1.45-$0.34Beat
Jul 30, 2025-$0.21-$1.55Miss
Apr 30, 2025-$0.24-$0.26Miss

Analyst view

Consensus price target
$46.33 ▲ +375.2%
Range $40.00 – $51.00
Rating: Buy
Buy 67% · Hold 27% · Sell 7%

Get free alerts on DBVT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.